<?xml version="1.0" encoding="UTF-8"?>
<p>The first DAAs, the protease inhibitors (PIs) boceprevir (BOC) and telaprevir (TVR), were approved in 2011 but had several limitations. Both PIs were accompanied by considerable adverse events like anemia or skin rash; their usage was mainly restricted to HCV genotype 1, and their efficacy was rather limited [
 <xref rid="CIT0002" ref-type="bibr">2–5</xref>]. Combination with pegylated interferon α (PEG-IFN α) was still required [
 <xref rid="CIT0006" ref-type="bibr">6</xref>]. Thus, a significant proportion of patients (eg, those with advanced cirrhosis, significant comorbidities) were not eligible for therapy, and many of those with mild disease chose to defer treatment [
 <xref rid="CIT0007" ref-type="bibr">7–9</xref>]. Furthermore, drug–drug interactions (DDIs) emerged as a new important challenge [
 <xref rid="CIT0010" ref-type="bibr">10</xref>, 
 <xref rid="CIT0011" ref-type="bibr">11</xref>]. BOC and TVR are substrates and inhibitors of P-glycoprotein (P-gp) and cytochrome P450 (CYP) 3A4 pathways that are frequently involved in DDIs [
 <xref rid="CIT0010" ref-type="bibr">10</xref>].
</p>
